Lung Cancer Clinical Trial

Clinical Trial Finder Lung Cancer Trials

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

See Locations Near You

Summary

This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung cancer (NSCLC) who have progressed after first- or second- line chemotherapy. It is hypothesized that KD019 can prolong survival compared with erlotinib.

View Eligibility Criteria

Eligibility Criteria

For Eligibility subjects must have:

failed one or two previous courses of therapy.
have no active brain metastasis. Treated non-active brain metastasis are acceptable.
cannot have received an Epidermal Growth Factor Receptors inhibitor (Tarceva [erlotinib] or Iressa [gefitinib]) in the past.
has demonstrated progressive disease.

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

8

Study ID:

NCT01487174

Recruitment Status:

Terminated

Sponsor:

Kadmon Corporation, LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Yale Cancer Center
New Haven Connecticut, 06519, United States
San Juan Oncology Associates
Farmington New Mexico, 87401, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

8

Study ID:

NCT01487174

Recruitment Status:

Terminated

Sponsor:


Kadmon Corporation, LLC

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
When Should I Consider Clinical Trials?
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider